Magnification-corrected photodynamic therapy
- 66 Downloads
To present a method for performing photodynamic therapy (PDT) with a constant predictable light fluence based on actual laser spot magnification.
A calibrated Gullstrand-type model eye with a scale of half circles in the centre of the artificial fundus was used for this study. The axial length of the model eye was set to different values ranging from 20 to 31 mm, and the actual laser spot magnification of four indirect condensing laser lenses were determined using a PDT laser unit.
Equations for determining the actual laser spot magnification were calculated for each laser lens. The total change in laser spot magnification from hyperopia (axial length 20 mm) to myopia (axial length 31 mm) was −20% to +24.8% for Mainster Standard lens (Ocular Instruments Inc, Bellevue, Washington, USA), −15.7% to +27.7% for Mainster Wide Field lens (Ocular Instruments Inc), −16.3% to +33.1% for Volk Transequator lens (Volk Optical Inc, Mentor, Ohio, USA), and −19.2% to +24.4% for Volk PDT Laser lens (Volk Optical Inc).
Axial length of the eye has a considerable effect on PDT laser spot magnification when an indirect laser lens is used. By calculating the actual laser spot magnification in conjunction with knowledge of the true greatest linear dimension of the neovascular lesion, the clinician may be able to deliver a constant predictable amount of light fluence to the fundus independent of the axial length of the PDT treating eye.
KeywordsPhotodynamic therapy Light fluence Choroidal neovascularization
The authors thank Bernhard Rassow for providing the model eye.
- 6.Ansari-Shahrezaei S, Ergun E, Stur M (2006) Digital area measurement of fundus landmarks. Graefes Arch Clin Exp Ophthalmol 244:649–653Google Scholar
- 9.Husain D, Gragoudas ES, Miller JW (1998) Photodynamic therapy. In: Berger JW, Fine SL, Maguire MG (eds) Age-Related Macular Degeneration. Mosby, St. Louis, pp 297–307Google Scholar
- 16.Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM, Birngruber R, van den Berg H, Strong A, Manjuris U, Gray T, Fsadni M, Bressler NM, Gragoudas ES (1999) Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 117:1161–1173PubMedGoogle Scholar
- 21.Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, Zografos L, Piguet B, Pournaras CJ, Donati G, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM (1999) Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 117:1177–1187PubMedGoogle Scholar
- 23.Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials—TAP Report 1. Arch Ophthalmol 117:1329–1345Google Scholar
- 24.Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials—TAP Report 2. Arch Ophthalmol 119:198–207Google Scholar